Table 1.
Impact of the HPV vaccination programme.
Age- and gender-standardised genital warts incidence rates estimates in the pre-vaccination (2006), transitional (2007–2008) and post-vaccination (2009–2013) periods—individuals affiliated to the MLOZ sick fund (Belgium).
Fig 1.
Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and qHPV vaccine uptake in individuals aged 16–22 years (A), 23–30 years (B), 31–40 years (C) and 41–59 years (D) affiliated to the MLOZ sick fund (Belgium) between 2006 and 2013 (standardised estimates).
Fig 2.
Vaccine effectiveness evaluation.
Flow chart summarising the number of women and person-years of follow-up available for the main analysis, with reasons for exclusion.
Table 2.
Characteristics of the vaccine effectiveness study population as a function of their vaccination status.
Table 3.
Estimated genital warts incidence rates per 100 000 person-years, stratified by potential risk factors for the population eligible for vaccine effectiveness assessment.
Table 4.
Crude and age-adjusted vaccine effectiveness (VE) estimates for genital wart by number of qHPV vaccine doses, time since vaccination and age at first vaccine dose.
Women eligible for HPV vaccination in Belgium and affiliated to the MLOZ sick fund.